LAG3 / IL-2 Reporter - Jurkat Recombinant Cell Line | 79813

LAG3 / IL-2 Reporter - Jurkat Recombinant Cell Line | 79813 | Gentaur US, UK & Europe Disrtribition

Category: Cell Line/Reporter Cell Line & Cell-Based Assays

Application: • Screen for activators or inhibitors of LAG3 signaling in a cellular context
• Characterize the biological activity of LAG3 and its interactions with ligands

Background: Lymphocyte-activation gene 3 (LAG3, CD223) is a cell surface protein that belongs to the immunoglobulin (Ig) superfamily. LAG3 is expressed on activated T cells, natural killer cells, B cells, and plasmacytoid dendritic cells. Its main ligand is MHC class II, to which it binds with higher affinity than CD4. It negatively regulates cellular proliferation, activation, and homeostasis of T cells in a similar fashion to CTLA-4 and PD-1, and has been reported to play a role in Treg suppressive function. A number of LAG3 antibodies are in preclinical development for treatments for cancer and autoimmune disorders. LAG3 may be a better immune checkpoint inhibitor target than CTLA-4 or PD-1 since antibodies to these two checkpoints are only activating effector T cells, and not inhibiting Treg activity while an antagonist LAG3 antibody can both activate effector T cells (by downregulating the LAG3 inhibiting signal) and inhibit induced (i.e. antigen-specific) Treg suppressive activity.

Description: Recombinant Jurkat T cell expressing firefly luciferase gene under the control of IL-2 response elements with constitutive expression of human LAG3 (lymphocyte-activation gene 3, CD223, GenBank Accession # NM_002286).

Product Type: Cell Line

Shippement Condition: -80°C